Search

News Adjuvant Treatment of Early Invasive HER2+ Breast Cancer −⁠ Results of the Katherine Study

Women with breast cancer found to have residual invasive disease during surgery after neoadjuvant chemotherapy and HER2-targeted therapy have a significantly worse prognosis. For these patients, the Czech Oncology Society ČLS JEP recommends adjuvant therapy with trastuzumab emtansine based on data from the Katherine clinical study. However, this treatment has not yet been covered by public health insurance, with reimbursement starting from March 1, 2021.

Source: Breast Carcinoma 8. 4. 2021

News Pathogenetic Mechanisms Underlying the Development and Progression of Interstitial Lung Diseases

Interstitial lung processes (ILP) represent an umbrella term for a wide range of nosological units that differ from each other in clinical course, prognosis, and pathogenesis. Most ILPs are characterized by inflammation or fibrosis of the interstitial space, leading to impaired gas exchange at the alveolocapillary membrane.

Source: Progressive Interstitial Pulmonary Processes 6. 12. 2022

News Is long-term treatment with ixekizumab sufficiently safe?

Psoriasis is a chronic inflammatory disease whose manifestations require long-term treatment. A poster presented at last year's European Academy of Dermatology and Venereology (EADV) congress summarizes ixekizumab safety data from monitoring lasting up to 5 years, based on nearly 18,000 patient-years (PY) in the treatment of this disease.

Source: Biological Treatment 8. 11. 2021

News Can Erdostein Help in Treating Infections Related to Biofilm Formation?

One of the reasons for the very difficult treatment of diseases caused by resistant bacterial strains is the significant ability of these infection-causing agents to form biofilms. What exactly is a biofilm? Which bacteria are likely to form it, and how can erdostein help in the fight against it?

Source: Cough Therapy 8. 4. 2022

News Anticonvulsants Are Associated with the Least Impact on Sexual Function in Bipolar Disorder Treatment

It is known that in patients with bipolar disorder, in addition to the illness itself, sexual dysfunction is adversely affected by psychotropic medications. A study by Spanish authors recently published in the Journal of Sexual Medicine compared the treatment of different groups of mood stabilizers in patients with bipolar disorder in terms of adverse effects on sexual function.

Source: Bipolar Disorder 8. 6. 2020

News Efficacy and Safety of Teriflunomide in the Treatment of Multiple Sclerosis in Children –⁠ Results of the TERIKIDS Study

Therapeutic options for multiple sclerosis in the pediatric population are limited. However, in June 2021, teriflunomide was approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) in pediatric patients aged 10–17 years in the European Union. The basis for this registration was the favorable results of the TERIKIDS study, which we summarize below. Teriflunomide thus became the first oral medication for 1st line treatment of RRMS in children and adolescents within the EU.

Source: Multiple Sclerosis 1. 6. 2022

News Association of Low TSH Levels in Hypothyroidism Therapy with Mortality Risk

Community surveys indicate that up to 53% of patients treated for hypothyroidism have serum thyroid-stimulating hormone (TSH) levels outside the normal range at some point. The negative effect of TSH levels above the upper reference limit is well documented, but according to two recently published population studies, mortality in patients treated with levothyroxine is also increased when TSH levels are below the lower reference limit.

Source: Thyroid Disorders 14. 9. 2022

News Systemic Manifestations of Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a chronic progressive disease characterized by remodeling of the pulmonary vessels, leading to the development of right-sided heart failure. Aside from the symptoms of right ventricular failure and pulmonary circulation impairment, patients with PAH also exhibit changes in other organ systems.

Source: Pulmonary hypertension (CTEPH, PAH) 16. 5. 2021

News COVID Pneumonia: How Can Erdosteine Help and What Did a Clinical Study Suggest?

When patients who have recovered from COVID pneumonia begin home treatment, they are often far from being symptom-free. General practitioners and outpatient pulmonologists often have to address these persistent symptoms. According to a study conducted by Recipharm, erdosteine may be a suitable adjunct treatment for these patients, even when they have negative COVID-19 tests. Why is this the case?

Source: Cough Therapy 12. 11. 2020

News Role of Transthyretin in the Development of Amyloidosis

Transthyretin (TTR), one of the transport proteins, tends to form extracellular deposits that accumulate in key organs, such as the heart and nerves. The formation of TTR deposits leads to the development of systemic amyloidosis, a disease with highly heterogeneous clinical manifestations. Warning signs may include carpal tunnel syndrome, among others. What is the physiological role of TTR in the body and what role does its structure play in the development of amyloidosis?

Source: Amyloidosis 20. 12. 2022

News Clinical Experiences with Reversing Dabigatran with Idarucizumab

Idarucizumab is an effective specific antidote to dabigatran, which very quickly negates its coagulative effects in cases of severe bleeding conditions or emergency surgical procedures. A Danish retrospective study examined clinical experiences with the use of idarucizumab for blocking dabigatran and related clinical outcomes.

Source: Anticoagulant Treatment 9. 12. 2021

Články časopisu Encyclopedia of CLL Subsets –⁠ a Unique Bioinformatics Tool and Database for Analysis of Subsets of Stereotypical B-Cell Receptors in CLL

Author of the article: T. Reigl, K. Stránská, V. Bystrý, A. Krejčí, A. Grioni, Š. Pospíšilová, N. Darzentas, K. Plevová Source: Klinická onkologie | Supplementum1/2019 10. 4. 2019

News What Next for Patients with CLL After Stopping Venetoclax?

Standard care for untreated patients with chronic lymphocytic leukemia (CLL) is therapy based on venetoclax. However, managing further treatment when venetoclax needs to be discontinued remains a relatively unexplored area without standardized protocols.

Source: Chronic Lymphocytic Leukemia 17. 7. 2020

News Temporary Interruption of Treatment or Dose Modification of Ibrutinib in CLL Patients

A team from the Mayo Clinic in Rochester, USA, published a study this March in the journal Cancer Medicine, focusing on aspects of ibrutinib therapy in real clinical practice. The authors evaluated the impact of dose modification or temporary interruption of the drug administration.

Source: Chronic Lymphocytic Leukemia 8. 6. 2020

News Meta-analysis of Efficacy and Safety of Third-Generation Antiseizure Medications in Adjunctive Treatment of Focal Seizures in Adults with Epilepsy

Epilepsy treatment is primarily symptomatic, aimed at reducing seizure frequency. However, more than 50% of patients do not achieve seizure freedom with monotherapy. Below we summarize the results of a meta-analysis comparing the efficacy and safety of third-generation antiseizure medications in the treatment of focal seizures in adults with epilepsy.

Source: Epilepsy 8. 6. 2023